Natera (NTRA) Launches $350M Proposed Follow-On Offering

Natera, Inc. (Nasdaq: NTRA) ("Natera"), a pioneer and global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of its common stock from Natera at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and SVB Leerink are acting as joint book-running managers for the offering. Baird, BTIG and Craig-Hallum are acting as co-managers for the offering.

You May Also Be Interested In

• SOPHiA Genetics closes $57.5M public offering at $4.75 per share
• Momentus files ATM offering of up to $75M in common stock
• ONEOK (OKE) files mixed shelf